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ABSTRACT 
In this present study, floating mucoadhesive tablets of Rosiglitazone were formulated to improve the gastric retention time and overall 
bioavailability. Different mucoadhesive polymers like HPMC K200 M, Na CMC, Carbopol 974P, Karaya gum, Chitosan and Xanthan gum were 
selected to formulate the tablets. Various formulations were prepared by using these polymers in different concentration. The pre-compression 
blend of Rosiglitazone mucoadhesive tablets were characterized with respect to angle of repose, bulk density, tapped density,  carr’s index and 
hausner’s ratio and all the results indicated that the blend was having good flow property and hence better compression properties. The 
swelling studies were performed for the formulations and the results depicted that all the formulations have a good swelling index. The drug 
release studies depicted that the formulations release the drug in first order. So based on the results, formulation RF13 was found to be an 
optimized formulation.  
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INTRODUCTION: 
Oral route is considered to be the most safest and convenient 
route of drug delivery. 90% of the drug available is designed 
to be given through the oral route due to patient acceptance. 
In conventional oral drug delivery, the drug resides for a 
shorter period time in absorption window, so bioavailability 
is less. Oral controlled drug delivery systems represent the 
most popular form of controlled drug delivery. This type of 
drug delivery systems releases the drug with constant or 
variable release rates to meet the drug regime. [1-3] 
The most preferable approach of oral controlled drug 
delivery is gastroretentive drug delivery systems (GRDDS), 
in which the dosage form retains in stomach for prolonged 
period increasing the Gastric residence time (GRT). GRDDS 
can be defined as a system which retains in the stomach for a 
sufficient period of time and releasing the active moiety in a 
controlled manner. [4] Over the last two decades, numbers of 
GRDDS have been designed to prolong GRT. The main aim of 
preparing GRDDS is to minimize the problem associated with 
existing oral sustained release dosage form and to develop 
patient benefited drug delivery. [5-7] 
So the present work is designed with antidiabetic drug, 
Rosiglitazone with different type of controlled release and 
mucoadhesive polymers with different concentration to 
optimize a formulation which will help to overcome the 
above problem. 
MATERIAL AND METHODS: 
The antidibetic drug Rosiglitazone is obtained from the 
authorized supplier with the certification of purity. Apart 
from the drug remaining polymers like Hydroxy Propyle 
Methyl Cellulose K 200M , sodium carboxy methyl   cellulose, 
Carbopol 974P, Karaya gum, Chitosan, Xanthan gum and 
other reaming excipients like sodium bicarbonate, 
magnesium stearate, talc, lactose too were obtained from 
authorized supplier. All the excipients and reagents used 
were of laboratory grade. 
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Pre-compressional evaluations [6-8] 
Solubility Studies 
The solubility of Rosiglitazone, in 0.1 N HCl at pH 1.2 was 
determined by phase equilibrium method. An excess amount 
of drug was taken into 20 mL vials containing 10 mL of 0.1 N 
HCL (pH 1.2). Vials were closed with rubber caps and 
constantly agitated at room temperature for 24 hrs using 
rotary shaker. After 24 hrs, the solution was filtered through 
0.2 µm Whatmann’s filter paper. The amount of drug 
solubilized was then estimated by measuring the absorbance 
at 248  nm using a UV spectrophotometer.  
The standard curves for Rosiglitazone was established in 0.1 
N HCl and from the slope of the straight line the solubility of 
Rosiglitazone was calculated. The studies were repeated in 
triplicate (n = 3), and mean was calculated.  
Drug-excipient compatibility studies  
Fourier transform infra-red spectroscopic studies: 
A Fourier transform – infra red spectrophotometer was used 
to study the non-thermal analysis of drug-excipient (binary 
mixture of drug: excipient 1:1 ratio) compatibility. The 
spectrum of each sample was recorded over the 450-4000 
cm-1. Pure drug of Rosiglitazone with physical mixture 
(excipients) compatibility studies were performed.  
Pre-compression Evaluation: 
Before formulating the drug substances into a dosage form, it 
is essential that drug polymer should be chemically and 
physically characterized. Preformulation studies gives the 
information needed to design the dosage form and provide a 
framework for the drug combination with pharmaceutical 
excipients in the manufacture of a dosage form. 
Powder flow properties 
Angle of repose 
 Angle of repose was determined by using funnel method. 
The frictional forces in the lose powder can be measured by 
Angle of repose. The tangent of Angle of repose is equal to 
the coefficient friction between the particles.  
θ = tan-1 (h / r) 
Where, θ is the angle of repose, h is the height in cm and r is 
the radius in cm.    
Compressibility index 
 It is an important measure that can be obtained from the 
bulk and tapped densities. A material having values less than 
20 to 30% is defined as the free flowing material, based on 
the apparent bulk density and tapped density, the percentage 
compressibility of the bulk drug was determined by using 
the following formula.                   
I = (DT – Db / DT )100 
Where, I is the Compressibility index, Dt is the tapped 
density of the powder and Db is the bulk density of the 
powder. 
Hausner’s ratio 
 It indicates the flow properties of the powder and is 
measured by the ratio of tapped density to the bulk density  
H = Dt / Db 
Where, H is the Hausner’s ratio Dt is the tapped density of 
the powder and Db is the bulk density of the powder. 
Preparation of Floating mucoadhesive tablets: [9] 
Floating mucoadhesive tablets containing 
Rosiglitazone were prepared by direct compression method. 
Various batches were prepared by changing the ratio of 
HPMC K200 M, NaCMC, Carbopol 974P, Karaya gum, 
Chitosan, Xanthan gum, NaHCO3, Talc, Magnesium stearate, 
Lactose. The drug and polymer mixture was prepared by 
homogeneously mixing the drug with HPMC K200 M, Na 
CMC, Carbopol 974P, Karaya gum, Chitosan, Xanthan gum, 
(Floating mucoadhesive polymers), Lactose in a glass mortar 
for 15 minutes. The Direct compressible powder is 
lubricated with talc and Magnesium Stearate for 2 minutes in 
Poly ethylene bag. The mixture (100 mg) was then 
compressed using a 6 mm diameter die in a 9-station rotary 
punching machine (Lab Press, India). The details of the 
formulation are mentioned in table no. 1. The different 
formulations were evaluated further for various post 
compression parameters. 
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Table No. 1: The Composition of Floating Mucoadhesive Tablets Of Rosiglitazone 
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Rosiglitazo
ne 
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 
HPMC 
K200 M 
4 8 12 - - - - - - - - - - - - - - - 
Na CMC - - - 4 8 12 - - - - - - - - - - - - 
Carbopol 
974P 
- - - - - - 4 8 12 - - - - - - - - - 
Karaya 
gum 
- - - - - - - - - 4 8 12 - - - - - - 
Chitosan - - - - - - - - - - - - 4 8 12 - - - 
Xanthan 
gum 
- - - - - - - - - - - - - - - 4 8 12 
NaHCO3 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 
Magnesiiun 
stearate 
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 
Talc 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Lactose 75 71 67 75 71 67 75 71 67 75 71 67 75 71 67 75 71 67 
Total 
Weight 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
 
Post- compression Evaluation: [10-12] 
Physicochemical characterization of tablets: 
    
The prepared Rosiglitazone Floating mucoadhesive tablets 
were studied for their physicochemical properties like 
weight variation, hardness, thickness, friability and drug 
content.  
A. Weight variation:   
The weight variation test is done by taking 20 tablets 
randomly and weighed accurately. Not more than two of the 
individual weight deviates from the average weight by ± 10 
% and none should deviate by more than twice that 
percentage. The percent deviation was calculated using the 
following formula: 
 % Deviation = (Individual weight – Average weight 
/ Average weight) X 100 
The average weight of tablets in each formulation was 
calculated and presented with standard deviation. 
 
Table No. 2: Pharmacopoeia specifications for tablet 
weight variation 
Average weight of tablets 
(mg) 
Maximum % of 
difference allowed 
80 or less ± 10 
More than 80 but less than 250 ± 7.5 
250 or more ± 5 
 
B. Tablet Thickness:    
     
The Thickness and diameter of the tablets from production 
run is carefully controlled. Thickness can vary with no 
change in weight due to difference in the density of 
granulation and the pressure applied to the tablets, as well as 
the speed of the tablet compression machine. Hence this 
parameter is essential for consumer acceptance, tablet 
uniformity and packaging. The thickness and diameter of the 
tablets was determined using a Digital Vernier caliper. Ten 
tablets from each formulation were used and average values 
were calculated. The average thickness for tablet is 
calculated and presented with standard deviation. 
C. Tablet Hardness:    
     
Tablet hardness is measured as the force required to break a 
tablet in a diametric compression test. Tablets require a 
certain amount of strength, or hardness and resistance to 
friability, to withstand the mechanical shocks during 
handling, manufacturing, packaging and shipping. The 
resistance of the tablet to chipping, abrasion or breakage 
under condition of storage transformation and handling 
before usage depends on its hardness. Six tablets were taken 
from each formulation and hardness was determined using 
Monsanto hardness tester and the average was calculated. It 
is expressed in Kg/cm2. 
D. Friability:     
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Tablet hardness is not an absolute indicator of the strength 
because some formulations when compressed into very hard 
tablets lose their crown positions. Therefore another 
measure of the tablet strength, its friability, is often 
measured. Tablet strength is measured by using Roche 
friabilator. Test subjects to number of tablets to the 
combined effect of shock, abrasion by utilizing a plastic 
chamber which revolves at a speed of 25 rpm for 4 minutes, 
dropping the tablets to a distance of 6 inches in each 
revolution. 
A sample of pre weighed tablets was placed in Roche 
friabilator which was then operated for 100 revolutions. The 
tablets were then de-dusted and reweighed. Percent 
friability (% F) was calculated as 
  
 
                                    Friability (%) = Initial weight of 10 tablets – final weight of 10 tablets X 100 
                                                                                       Initial weight of 10 tablets 
Where, Wo is the initial weight of the tablets before the test and     W is the final weight of the tablets after test. 
 
E. Assay: 
Six tablets of each formulation were taken and amount of 
drug present in each tablet was determined. Powder 
equivalent to one tablet was taken and added in 100 mL of 
pH 6.8 phosphate buffer followed by stirring for 10 minutes. 
The solution was filtered through a 0.45 μ membrane filter, 
diluted suitably and the absorbance of resultant solution 
was measured by using UV-Visible spectrophotometer at 
248 nm using pH 6.8 phosphate buffer. 
In vitro Buoyancy studies:  
The in vitro buoyancy was determined by floating lag time 
and total floating time. The tablets were placed in a 100ml 
beaker containing 0.1N HCL. The time required for the tablet 
to rise to the surface and float was determined as floating lag 
time (FLT) and duration of time the tablet constantly floats 
on the dissolution medium was noted as Total Floating Time 
respectively (TFT). 
In vitro release studies: [13-14]  
The drug release rate from Floating mucoadhesive tablets 
was studied using the USP type II dissolution test apparatus. 
Tablets were supposed to release the drug from one side 
only therefore an impermeable backing membrane was 
placed on the other side of the tablet. The tablet was further 
fixed to a 2x2 cm glass slide with a solution of cyanoacrylate 
adhesive. Then it was placed in the dissolution apparatus. 
The dissolution medium was 900 ml of 0.1N HCl at 50 rpm at 
a temperature of 37 ± 0.5 °C. Samples of 5 mL were collected 
at different time intervals up to 12 hrs and analyzed after 
appropriate dilution by using UV Spectrophotometer at 237, 
248, 227  nm.  
In vitro bioadhesion strength:  
Bioadhesion strength of tablets were evaluated using a 
microprocessor based on advanced force gauge equipped 
with a motorized test stand (Ultra Test Tensile strength 
tester, Mecmesin, West Sussex, UK) according to method 
describe as it is fitted with 25 kg load cell, in this test porcine 
membrane was secured tightly to a circular stainless steel 
adaptor and the Floating mucoadhesive tablet to be tested 
was adhered to another cylindrical stainless steel adaptor 
similar in diameter using a cyanoacrylate bioadhesive. 
Mucin 100 µL of 1% w/v solution was spread over the 
surface of the mucosa and the tablet immediately brought in 
contact with the mucosa. At the end of the contact time, 
upper support was withdrawn at 0.5 mm/sec until the tablet 
was completely detached from the mucosa. The work of 
adhesion was determined from the area under the force 
distance curve.  
The peak detachment force was maximum force to detach 
the tablet from the mucosa.  
 Force of adhesion = Bioadhesion strength x 9.8 
    1000   
                       Bond strength = Force of adhesion  
         Surface area  
Moisture absorption: 
Agar (5% m/V) was dissolved in hot water. It was 
transferred into petridishes and allowed to solidify. Six 
Floating mucoadhesive tablets from each formulation were 
placed in a vacuum oven overnight prior to the study to 
remove moisture, if any, and laminated on one side with a 
water impermeable backing membrane. They were then 
placed on the surface of the agar and incubated at 37°C for 
one hour. Then the tablets were removed and weighed and 
the percentage of moisture absorption was calculated by 
using following formula: 
%Moisture Absorption =Final weight – Initial weight x 100 
                                                Initial weight  
Kinetic analysis of dissolution data: [15-21]   
To analyze the in vitro release data various kinetic models 
were used to describe the release kinetics.  
1. Zero – order kinetic model – Cumulative % drug 
released versus time. 
2. First – order kinetic model – Log cumulative percent 
drug remaining versus time. 
3. Higuchi’s model – Cumulative percent drug released 
versus square root of time. 
4. Korsmeyer equation / Peppa’s model – Log cumulative 
% drug released versus log time. 
In vivo studies - pharmacokinetic studies: 
To investigate the peak plasma concentration 
pharmacokinetic studies were carried out. The In vivo 
studies were conducted on Wistar male rats weighing 250-
300 gm. They were housed in polypropylene cages and had 
free access to food and water. The dose of rosiglitazone was 
calculated as per the body weight of animals and developed 
tablets were formulated considering the calculated dose. The 
animal protocol was approved by the Animals Ethical 
Committee. The optimised Floating mucoadhesive matrix 
tablets were administered orally. Blood samples were 
collected for over 24 hrs according to a predetermined 
sample collection schedule. Various pharmacokinetic 
parameters like C max, T max, AUC   were   determined. [22] 
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RESULT AND DICSUSSION: 
Solubility Studies:            
Table No. 3: Solubility studies 
S.No Medium Amount present (µg/mL) 
      1 Water 30.67 
      2 Methanol 100.98 
      3 0.1 N HCL 48.82 
 
Drug –Polymer Compatibility Studies by FTIR 
 
Figure No.1: FTIR of Rosiglitazone pure drug. 
 
Figure No.2: FTIR Spectra of Optimised Formulation 
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Pre-compression Evaluation: 
 
Figure No.3: Angle of Repose for the obtained formulations 
 
 
Figure No.4: Carr’s Index for the obtained formulations 
 
 
 Figure No.5: Hausner’s Ratio Index for the obtained formulations 
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Post-compression Evaluation: 
Table No.4: Evaluation of floating mucoadhesive tablets of Rosiglitazone 
Formulation 
Code 
Thickness 
(mm)  
Average  
Weight (mg)  
Hardness 
(Kg/cm2) 
Friability 
(%) 
 
Content 
uniformity 
Total Floating 
time (Hours) 
Floating Lag 
time (Sec) 
RF1 4.59±0.09 98.25±0.28 5.2±0.15 0.35±0.04 95.36±0.27 >12 35.3±0.37 
RF2 4.91±0.08 99.35±0.24 5.6±0.13 0.29±0.02 99.25±0.24 >12 43.0±0.34 
RF3 4.87±0.04 95.61±0.19 5.9±0.19 0.51±0.06 98.14±0.21 >12 48.1±0.36 
RF4 4.39±0.06 99.39±0.24 5.4±0.09 0.48±0.02 100.2±0.19 >12 39.2±0.31 
RF5 4.99±0.10 99.48±0.17 5.8±0.13 0.63±0.04 97.45±0.24 >12 32.9±0.30 
RF6 4.89±0.08 98.67±0.39 5.9±0.17 0.81±0.09 98.61±0.30 >12 25.6±0.29 
RF7 4.68±0.04 97.52±0.25 5.0±0.20 0.23±0.08 99.75±0.29 >12 12.0±0.28 
RF8 4.90±0.11 98.15±0.20 5.3±0.17 0.28±0.05 99.87±0.34 >12 15.7±0.24 
RF9 4.19±0.06 99.45±0.26 5.7±0.18 0.61±0.10 96.10±0.18 >12 17.0±0.23 
RF10 4.72±0.02 100.0±0.17 5.9±0.16 0.38±0.05 99.38±0.24 >12 39.2±0.18 
RF11 4.68±0.08 98.31±0.16 5.4±0.15 0.47±0.07 97.82±0.18 >12 45.6±0.25 
RF12 4.39±0.03 97.45±0.31 5.1±0.24 0.59±0.11 99.34±0.19 >12 110.0±0.17 
RF13 4.57±0.15 99.12±0.19 5.3±0.17 0.67±0.08 96.92±0.35 >12 45.0±0.19 
RF14 4.38±0.06 97.35±0.24 5.8±0.24 0.15±0.04 97.24±0.27 >12 55.2±0.25 
RF15 4.29±0.01 98.46±0.21 5.1±0.26 0.43±0.09 95.89±0.26 >12 51.0±0.26 
RF16 4.35±0.08 99.14±0.23 5.0±0.28 0.57±0.12 99.75±0.29 >12 70.8±0.19 
RF17 4.62±0.10 97.32±0.21 5.9±0.21 0.43±0.05 97.19±0.30 >12 74.6±0.30 
RF18 4.64±0.15 99.47±0.20 5.7±0.15 0.37±0.09 98.69±0.21 >12 130±0.38 
 
In vitro release studies:  
 
Figure No.6: In vitro Dissolution study of RF 1 to RF 9 
 
 Figure No.7: In vitro Dissolution study of RF 10 to RF 18 
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Moisture absorption, bioadhesion strength values of selected formulations 
Table No. 5: Moisture absorption, bioadhesion strength values of selected formulations. 
Formulation 
Code 
Moisture absorption 
Bioadhesion strength 
Peak 
detachment 
force (N) 
Work of 
adhesion 
(mJ) 
RF13 66±0.33 4.8±0.12 23.41±6.18 
                                     Each value represents the mean±SD (n=3) 
 
Release kinetics:      
Data of in vitro release studies of formulations which were 
showing better drug release were fit into different equations 
to explain the release kinetics of Rosiglitazone release from 
mucoadhesive tablets. The data was fitted into various 
kinetic models such as zero, first order kinetics, higuchi and 
korsmeyer peppas mechanisms and the results were shown 
in below table. 
 
Table No 6: Table of release kinetics and correlation factors 
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0 0 0     2.000       100 4.642 4.642 0.000 
19.7 0.5 0.707 1.294 -0.301 1.905 39.400 0.0508 -0.706 80.3 4.642 4.314 0.327 
26.92 1 1.000 1.430 0.000 1.864 26.920 0.0371 -0.570 73.08 4.642 4.181 0.461 
29.7 2 1.414 1.473 0.301 1.847 14.850 0.0337 -0.527 70.3 4.642 4.127 0.514 
34.06 3 1.732 1.532 0.477 1.819 11.353 0.0294 -0.468 65.94 4.642 4.040 0.602 
40.04 4 2.000 1.602 0.602 1.778 10.010 0.0250 -0.398 59.96 4.642 3.914 0.728 
46.72 5 2.236 1.670 0.699 1.727 9.344 0.0214 -0.330 53.28 4.642 3.763 0.879 
49.25 6 2.449 1.692 0.778 1.705 8.208 0.0203 -0.308 50.75 4.642 3.702 0.939 
53.86 7 2.646 1.731 0.845 1.664 7.694 0.0186 -0.269 46.14 4.642 3.587 1.055 
60.64 8 2.828 1.783 0.903 1.595 7.580 0.0165 -0.217 39.36 4.642 3.402 1.240 
67.85 9 3.000 1.832 0.954 1.507 7.539 0.0147 -0.168 32.15 4.642 3.180 1.462 
70.34 10 3.162 1.847 1.000 1.472 7.034 0.0142 -0.153 29.66 4.642 3.095 1.546 
86.95 11 3.317 1.939 1.041 1.116 7.905 0.0115 -0.061 13.05 4.642 2.354 2.287 
99.64 12 3.464 1.998 1.079 -0.444 8.303 0.0100 -0.002 0.36 4.642 0.711 3.930 
 
 
 
Figure No.8: Zero order plot of optimized formulation 
 
Figure No.9: Higuchi plot of optimized formulation 
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Figure No.10: Koresmeyer-peppas plot of optimized 
formulation 
 
Figure No.11: First order plot of optimized formulation 
Based on the all studies RF13 formulation was found to be 
better when compared with all other formulations. This 
formulation was following Higuchi mechanism with 
regression value of 0.980.  
In vivo Studies - Pharmacokinetic Studies: 
All the pharmacokinetics parameters displayed in Table. 
Mean time to reach peak drug concentration (Tmax) was 1.75 
hours, while mean maximum drug concentration (Cmax) was 
640 mg/mL. The values for Cmax, Tmax, AUC were found to be 
comparable indicating that their sustained release patterns 
were similar. 
Table No 7:    Pharmacokinetic parameters of 
optimized formulation 
S.No Parameter Rosiglitazone 
1 Cmax 640 mg/mL (±0.22) 
2 T max (hr) 1.75 hours(± 0.56) 
3 AUC 3.62 mg/L · h (±1.24) 
 
The solubility studies indicated that the drug is having less 
solubility in water as compared to methanol and 0.1N HCl. 
The solubility data confirms that rosiglitazone is one of the 
best model drug to be formulated as GRDDS. The FTIR 
studies indicated that the drug and polymers have no 
interaction. There was no change is the basic drug peaks. The 
angle of repose of all the formulations is under 30 degree. 
Hence we can say that the powder blend has a good flow 
property. The Carr’s Index and Hausner ratio results also 
predict that the powder blend has a good flow property. So 
direct compression technique can be used to formulate the 
tablets. The mean thickness of all the formulations ranges 
between 4.19 to 4.99 mm. It can be concluded that all the 
tablets have uniform size and shape. The weight of the 
tablets ranged between 95.61mg to 100mg.  The maximum 
weight variation limit is ± 7.5 for tablets ranging 80mg to 
250mg. So the prepared tablets were within the prescribed 
range. The hardness of the tablets ranged from 5-6 Kg/cm2. 
The friability test shows that all the tablets have friability 
below 1. This suggests that the tablets prepared had a good 
mechanical strength and resistance. All the formulations 
have good drug content. The floating lag time of the tablets 
was lowest for RF7 12 sec and highest for RF18 130sec. The 
in-vitro drug release was performed using 0.1N HCl at pH 1.2 
for 12hrs. The results indicate that the lowest drug release 
was for formulation RF12 which contains high concentration 
of Karaya Gum. The highest drug release is found in 
formulation RF13 which contains chitosan. There is a 
significant decrease in the drug release rate with increase 
proportion of karaya gum. The formulations containing 
carbopol and chitosan showed a uniformity in drug release. 
The bioadhesion strength of RF13 was found to be optimum 
to satisfy the need of mucoadhesion for prolonged period of 
time. Various kinetics study were performed and it was 
found that RF13 formulation was found to be better when 
compared with all other formulations. This formulation was 
following Higuchi mechanism with regression value of 0.980. 
The in-vivo pharmacokinetics studies showed that the drug 
reaches the maximum concentration in 1.75hr. The Cmax and 
AUC data predicts that the drug has a good oral 
bioavailabilty. 
CONCLUSION 
Form the obtained results, it can be concluded that the drugs 
can be easily formulated as GRDDS using different ratios of 
rate controlling polymers like chitosan, NaCMC, HPMC K200 
and Carbopol 934. Chitosan is found to be promising 
polymer in controlling the rate and extent of drug release 
from the dosage form. Further work can be carried out to 
design more GRDDS. 
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